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Calcium Channel Blocker D-cis-Diltiazem Does Not Slow Retinal Degeneration in
the PDE6B Mutant rcd1 Canine Model of Retinitis Pigmentosa
Abstract
Purpose: D-cis-diltiazem, a calcium channel blocker, has been reported to enhance photoreceptor survival
in the rd mouse, a model of retinitis pigmentosa (RP) resulting from mutation of the PDE6B gene. We
tested the hypothesis that diltiazem treatment would similarly rescue the canine rcd1 model of RP, which
is also caused by a null mutation in the PDE6B gene.
Methods: D-cis-diltiazem was delivered orally twice daily to rcd1 affected dogs beginning at 4 weeks of
age; untreated age-matched rcd1 dogs served as controls. At 14 weeks, electroretinograms (ERG) were
performed on all animals; 14 dogs were euthanized at this age, and 2 dogs at 25 weeks of age. Eyes were
enucleated, fixed, and processed for routine histological examination.
Results: No significant differences were found in ERG or histopathologic parameters between diltiazemtreated and untreated rcd1 dogs. Neither rcd1 group showed a rod b-wave; ERGs evoked by single white
flashes (dark- or light-adapted) and flicker were also identical between groups. Similarly, treated and
untreated animals did not differ in the degree of preservation of the photoreceptor layer, confirmed in cell
counts within the outer nuclear layer.
Conclusions: Treatment of rcd1 affected dogs with D-cis-diltiazem did not modify the photoreceptor
disease when results were assessed using either ERG or histopathologic criteria. The positive
photoreceptor-rescue effect of calcium channel blockers reported in the rd mouse was thus not
generalizable to another species with retinal degeneration due to mutation in the PDE6B gene. Caution
needs to be exerted in extrapolation to the comparable human forms of RP.
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Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis
pigmentosa
Susan E. Pearce-Kelling,1 Tomas S. Aleman,2 Amanda Nickle,3 Alan M. Laties,2 Gustavo D. Aguirre,1Samuel G.
Jacobson,2Gregory M. Acland1
1

Baker Institute, College of Veterinary Medicine, Cornell University, Ithaca, NY; 2Department of Ophthalmology, University of
Pennsylvania, Philadelphia, PA; 3Retinal Disease Studies Facility, University of Pennsylvania, Kennett Square, PA
Purpose: D-cis-diltiazem, a calcium channel blocker, has been reported to enhance photoreceptor survival in the rd
mouse, a model of retinitis pigmentosa (RP) resulting from mutation of the PDE6Bgene. We tested the hypothesis that
diltiazem treatment would similarly rescue the canine rcd1 model of RP, which is also caused by a null mutation in the
PDE6B gene.
Methods: D-cis-diltiazem was delivered orally twice daily to rcd1 affected dogs beginning at 4 weeks of age; untreated
age-matched rcd1 dogs served as controls. At 14 weeks, electroretinograms (ERG) were performed on all animals; 14
dogs were euthanized at this age, and 2 dogs at 25 weeks of age. Eyes were enucleated, fixed, and processed for routine
histological examination.
Results: No significant differences were found in ERG or histopathologic parameters between diltiazem-treated and
untreated rcd1 dogs. Neither rcd1 group showed a rod b-wave; ERGs evoked by single white flashes (dark- or lightadapted) and flicker were also identical between groups. Similarly, treated and untreated animals did not differ in the
degree of preservation of the photoreceptor layer, confirmed in cell counts within the outer nuclear layer.
Conclusions: Treatment of rcd1 affected dogs with D-cis-diltiazem did not modify the photoreceptor disease when results
were assessed using either ERG or histopathologic criteria. The positive photoreceptor-rescue effect of calcium channel
blockers reported in the rd mouse was thus not generalizable to another species with retinal degeneration due to mutation
in the PDE6B gene. Caution needs to be exerted in extrapolation to the comparable human forms of RP.

is mutant gene-specific, there are RP patients known to share
the same molecular causation [6,11-13].
Prompted by the report of neuroprotection with D-cisdiltiazem in the rd mouse [1], we tested the hypothesis that
rescue may be similarly detectable in the rcd1 dog. Histopathologic and electroretinographic criteria were used to evaluate
rcd1 dogs fed the human cardiac medication (Cardizem™)
during a relatively early period of the retinal disease in this
species.

Finding treatments that would slow progression of the
relentless loss of vision in human retinitis pigmentosa (RP) is
a major goal of research into these genetically heterogeneous
inherited retinal degenerations. The ideal therapy would be
simply and safely administered and would be immediately
available for use by patients. Hope was raised recently that
one such pharmaceutical treatment for RP may be forthcoming with the report that D-cis-diltiazem, an available oral calcium channel blocker used for human cardiac disease, may
have efficacy to rescue photoreceptors in the rd (retinal degeneration) mouse model of human RP [1]. The pathophysiology of retinal degeneration in the rd mouse has been explored over decades, and the molecular basis of the disease is
now known to be a mutation in the PDE6B gene [2-6]. An
advantage of discovering measurable benefit in this murine
model of RP is that testing can be promptly advanced to a
large animal model, the rcd1(rod-cone dysplasia 1) dog, also
known to have severe retinal degeneration caused by a similar
deficiency in cyclic guanosine monophosphate (cGMP)-phosphodiesterase (PDE) activity resulting from an autosomal recessive PDE6B mutation [7-10]. Further, if therapeutic effect

METHODS
Animals: All experimental procedures were conducted in accordance with institutional guidelines and those of the Institute for Laboratory Animal Research (Guideline for the Care
and Use of Laboratory Animals) and the US Public Health
Service (Public Health Service Policy on Humane Care and
Use of Laboratory Animals). Seventeen rcd1-affected dogs
were used for this study. The animals were the product of 4
different litters born within one month of each other, representing affected x affected and affected x carrier matings. Disease genotype of the latter group was established by molecular diagnostic testing for the mutation in PDE6B causing rcd1
[14]. Schedules for initiation of dosing, electroretinography,
enucleation, and termination of the study were adjusted so
that animals of comparable ages were studied. The dogs were
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maintained in indoor runs with controlled cyclic illumination.
Following weaning from the mother, the dogs were fed ad
libitum with commercial dog food diets (Purina Puppy Chow,
Ralston Purina, St. Louis, MO; Hi Tor beef, Triumph Pet Industries, Warwick, NY).
Treatment Regimen: Beginning at 4 weeks of age, 10
rcd1-affected dogs had oral administration of D-cis-diltiazem
(Cardizem™) tablets or sustained release capsules at a dose
of 40 mg/kg/day (tablets = divided doses 2 times/day for 5
days; sustained release capsules = one time/day weekends).
Seven age-matched rcd1-affected dogs served as untreated
controls. At this age, the retinal photoreceptors show only the
earliest stages of visual cell degeneration [8,15]. The daily
dose and frequency of administration were approximately the
same (40 mg/kg) as those used in the rd mouse (21 and 54 mg/
kg) study [1]. This dose is more than 6.6-10 fold higher than
the dose currently used in the clinical management of dogs
with cardiac disease (R. Gleed, Cornell University, personal
communication, October 1999), and just below the 50 mg/kg
single daily dose that produces severe toxicity in dogs when
administered daily for 30 days (Hoechst Marion Roussel, personal communication, October 1999). Prior to the initiation
of dosing, the dogs were weighed and amount of drug to be
administered determined. This amount was adjusted on a
weekly basis based on the animals’ weight. Treatment was
continued until 14 weeks of age (n=8) and 25 weeks of age
(n=2).
Electroretinography: Full field electroretinograms (ERG)
were recorded on all 17 rcd1-affected dogs at about 14 weeks
of age. For 10 of the dogs, this recording was after 10 weeks
of treatment with D-cis-diltiazem and these results were com-

pared with ERGs from the group of untreated dogs (n=7). For
the treatment group, no medication was given after the last
dose on the day before ERG testing to permit time (>20 h) for
drug clearance, which is reported to be about 2.5 h [16]. The
ERGs were performed using a computer-based system (EPICXL, LKC Technologies, Inc., Gaithersburg, MD) and bipolar
contact lens electrodes (Hansen Ophthalmics, Iowa City, IA).
Animals were anesthetized with an intramuscular injection of
acepromazine (0.08 mg/kg) followed by intravenous doses of
ketamine (15 mg/kg). Pupils were dilated with cyclopentolate
(1%) and phenylephrine (2.5%). In fully dark-adapted (overnight) dogs, a dim blue flash (W47A, -1.9 log scot-cd.s.m-2)
was used to elicit a rod ERG b-wave. To elicit a maximal mixed
rod and cone response, single white flashes of light (0.8 log
scot-cd.s.m-2) were used. Following light adaptation, cone
ERGs were recorded on a rod desensitizing white background
(1.5 log cd.m-2 with 1 Hz; 0.6 log cd.m-2 background with 29
Hz); 5-20 responses were averaged for light-adapted recordings. Waveforms were measured conventionally [17]. Treated
and untreated groups were compared using amplitude criteria
with unpaired two-tailed t-tests. Results are presented as mean
values±standard deviation (SD).
Histopathology: At 14 weeks of age (treated=8; untreated=6),
and 25 weeks (treated=2), dogs were euthanized with a barbiturate overdose and their eyes enucleated and processed for
microscopic examination. Both eyes from the dogs at the 14
week time point and one eye each from the dogs at the 25
week time point were fixed in Bouin’s solution, embedded in
paraffin, 5 µm sections were cut from the central (pupil/optic
nerve) block and stained with hematoxylin and eosin. The fellow eyes from the two dogs at the 25 week time period were
fixed in formaldehyde/glutaraldehyde and post fixed in osmium tetroxide. After embedding in Epon, 1 µm sections were
cut from the central superior and inferior meridians, and stained
with azure II, methylene blue. Fixation and sectioning methods are published [18].
Photoreceptor rescue was assessed by evaluating the structural integrity of the visual cell layer by an examiner masked
as to the treatment status of the dogs. For quantitative evaluation of rescue, nuclei in the outer nuclear layer (ONL) were
counted in three regions from both the superior and inferior
quadrants (area 1 was central, area 2 was equatorial, and area
3 was peripheral). These areas are located within 2000 µm
from the optic nerve head, midway between the optic nerve
head and the ora serrata, and within 2000 µm from the ora
serrata, respectively [19]. At three locations within each section, the number of rows of photoreceptor nuclei was counted
[15] and the average of these values used in the analyses. Differences between treated and untreated groups both by retinal
area, and for all areas, were analyzed using the unpaired twotailed t-test. Results are presented as mean values±SD.

Figure 1. Rod, mixed cone-rod, and cone electroretinograms. Rod,
mixed cone-rod, and cone electroretinograms in a representative normal dog and the untreated and D-cis-diltiazem-treated rcd1-affected
dogs in this study. All ERG responses of rcd1 dogs are shown by
overlaying the waveforms from each group. Stimulus onset is at trace
onset. Calibrations for amplitude and timing are below and to the
right of the responses.

RESULTS
The medication was well tolerated in all but two of the
treated dogs. One dog developed drug-associated toxicity 12
days after the start of dosing. This was characterized by depressed activity including inability to stand and walk, hypoten43
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sion, and labored breathing. These clinical signs lasted 5 days.
Diltiazem treatment was discontinued when the adverse effects became apparent with no medication administered between days 12 through 21 of the study. Once treatment was
resumed, there was no recurrence of the drug-associated reactions. A second dog showed similar but milder adverse effects
beginning on drug day 24, and lasting 2 days. Treatment was
withheld for 1 day, and the effects disappeared and did not
recur after treatment was resumed.
Electroretinograms (ERGs) from a representative normal
dog and the two groups of rcd1-affected dogs at 14 weeks of
age are illustrated (Figure 1). The dim blue flash elicits a rod
b-wave in the normal of about 100 µV [20-23], but there was
no detectable rod b-wave to this stimulus in either the diltiazem
treated or untreated rcd1-affected dogs. The mixed rod and
cone ERG in response to the bright white flash in the normal
dog has an a-wave of 150 µV and a b-wave of 250 µV. Affected animals in both groups have very reduced but measurable b-waves. Cone ERG b-waves in response to the 1 Hz
stimulus in the normal dog were about 30 µV while affected
animals had reduced amplitudes. Unlike the normal animal,
dark- and light-adapted waveforms are very similar in affected
animals suggesting a cone origin of the dark-adapted ERGs to
the maximal stimulus. Responses to 30 Hz flicker were also
reduced in amplitude compared to the normal. These findings
confirm the presence of rod and cone functional abnormalities in the disease [24]. Inspection of the waveforms showed
no obvious amplitude or timing differences between diltiazemtreated and untreated rcd1-affected dogs.
Histologic examination of the retinas showed no apparent differences in the structural preservation of the photoreceptor layer between treated and untreated rcd1-affected dogs
(Figure 2). Normal control dogs had a well developed photo-

receptor layer with elongated inner and outer segments, and
an ONL approximately 10 nuclei in thickness. In contrast, the
rcd1-affected dogs, whether diltiazem treated or not, showed
the same degree of photoreceptor and ONL loss at 14 weeks
of age. In both groups, the outer segment layer was fragmented
and, for the most part, lost, and the inner segments were diminutive. The remaining photoreceptors were mainly cones,
and these appeared as broadened and club-shaped, possibly
due to the disappearance from the photoreceptor mosaic of
the adjacent rods which provided lateral support. In the 25
week old treated animals, there was further reduction in ONL
thickness. Variation in outer segment length occurred between
sections and retinal regions (at 14 and 25 weeks), but a qualitative survey showed no consistent differences between treated
and untreated retinas at the ages examined.
ERG and histopathological data from all 14 week old rcd1affected dogs with and without diltiazem treatment are summarized in Figure 3. For the three measurable ERG responses
(Figure 3A), the group treated with diltiazem (n=10) did not
differ statistically from the group that was untreated (n=7).
Dark-adapted ERG b-wave amplitudes in response to the maximal white stimulus in untreated (14±4 µV) and treated (15±8
µV) animals were not significantly different (p=0.68). Lightadapted 1 Hz ERG amplitudes in the untreated (14±4 µV) and
treated (14±7 µV) groups were not different; 29 Hz amplitudes of the untreated (11±4 µV) and treated (11±5 µV) groups

Figure 3. ERG and retinal morphometric comparisons of treated and
untreated dogs. ERG and morphometric comparisons of D-cisdiltiazem-treated (white bars) and untreated (black bars) rcd1-affected
dogs (14 weeks of age). A: Histograms of average ERG amplitudes
for the three measurable responses. B: Histograms of average number of rows of photoreceptor nuclei remaining in rcd1 dogs with or
without D-cis-diltiazem treatment. Central (area 1), equatorial (area
2, as shown in Figure 2), and peripheral (area 3) regions were analyzed in both superior and inferior retina. Summary histograms of all
data are at right. Error bars represent SD.

Figure 2. Normal and affected retinal histology. Retinal histology in
a representative normal dog (age 21 weeks) and rcd1-affected dogs:
one untreated animal (age 14 weeks) and two D-cis-diltiazem-treated
animals (ages 14 and 25 weeks). Upper and lower panels represent
superior and inferior regions of the retina (area 2), respectively. Calibration bar at lower right, 20 µm.
44
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were also not significantly different (p=0.9).
Morphometry (Figure 3B) was consistent with ERG.
There was no statistically significant difference in rows of ONL
nuclei between treated (n=10) and untreated (n=6) 14 week
old rcd1-affected dogs in any of the six retinal areas or in the
combined totals of all retinal areas (Figure 3B). In no single
area did the mean number of ONL nuclei in treated and untreated groups differ by more than 0.4 rows; in all six areas
examined, there was no statistical difference between the
groups (p=0.3 in all cases). When the retinal areas were combined and comparison made by groups, ONL nuclei in the
treated (mean=3.1, SD=0.4 rows) and untreated (3.1±0.3 rows)
groups also did not differ (p=0.9). In the two treated dogs examined at 25 weeks of age, the retinal disease had progressed
still further, and the ONL was reduced to 1.5 and 1.6 rows of
nuclei respectively. Untreated rcd1-affected animals at age 21
weeks (n=4) showed 2.0 rows of nuclei (SD=0.3); and at 27
weeks (n=1) there were 1.9 rows of nuclei. This degree of
severity of the retinal degeneration in untreated animals was
expected from the natural history of the disease previously
described [8,15,25].

be that this treatment can retard degeneration at ages greater
than 25 weeks in the canine model. However, the absence of
photoreceptor rescue in the rcd1 dog in contrast to the rd mouse
is not likely to be due to differences in either the initiation of
dosing, or alternatively, differences in bioavailability of drug
to the target tissue. The 4 week age chosen for the beginning
of treatment in the dog is comparable to postnatal day 9 in the
mouse. Both species display arrested retinal photoreceptor
differentiation and the very early stages of rod cell death are
apparent [6,15,20,28]. Likewise, the dosing used appears comparable in terms of actual daily drug administration. Evidence
that we are close to the maximal tolerable dose is based not
only on the information made available by the drug manufacturer (Hoechst Marion Roussel, personal communication,
October 1999), but also on the fact that two dogs showed drugassociated toxicity, which disappeared with temporary cessation of therapy, but was definitely severe. Time was allowed
for clearance of the drug from the circulation [16] before ERGs
were performed, but whether there are more prolonged effects
that could complicate interpretation of ERG results needs to
be determined [1].
Whether providing confirmation or contradiction, studies like the present one represent an early attempt to follow a
stepwise, conservative, and logical path en route to clinical
trials of human retinal degeneration. Decades of basic and clinical scientific work in the field of retinal degenerations now
permit comparing response to intervention in small animals
with that in large animals having a similar molecular cause of
disease before embarking on human trials. In this regard, we
are not restricted to small and large animal models of human
autosomal recessive RP due to PDE6B mutation. There are
genetically-engineered murine and naturally-occurring avian
forms of early-onset retinal degeneration from abnormal retinal guanylate cyclases [29,30], genetically-engineered murine
and naturally-occurring canine models of autosomal recessive
early-onset retinal degeneration from mutations in RPE65 [3133], and certain genetically-engineered mice, rats, and swine
with rhodopsin gene mutations modeling human dominant RP
[34-36]. Promising results in murine and canine models of the
RP3 form of X-linked RP may also become the pre-clinical
path for human trials of this severe form of retinal degeneration [37,38].
The current study represents to our knowledge the fourth
report of use of calcium channel blockers to intervene in a
hereditary retinal degeneration. The Drosophila retinal degeneration B (rdgB) mutant was reported to show successful rescue [39], while a line of P23H rhodopsin mutant rats were
recently found to show no neuroprotective effect when the
exact same protocol used in the rd mouse was studied in this
animal model of RP [27]. In conclusion, our results should
signal the beginning of greater depth of investigation of the
effects of calcium channel blockers and related drugs in both
the canine and murine PDE6B mutant models. The hope that
an available oral medicine could slow the visual loss of this
specific molecularly-defined subset of RP patients is too attractive to abandon without further study.

DISCUSSION
Photoreceptor rescue by D-cis-diltiazem in the naturally-occurring PDE6B murine model of RP was the first successful
use of a pharmaceutical to alter the abnormal cellular mechanisms resulting from a mutant gene causing retinal degeneration [1]. For this reason, it represented a landmark observation in the history of investigation of the cGMP cascade, its
perturbation in disease, and strategies to modify the pathophysiology. The deficiency of c-GMP PDE in photoreceptors
of the rd mouse resulting from a null mutation in the PDE6B
gene leads to a cascade of events culminating in rod and then
cone cell death [26]. The suspected mechanism of diltiazem’s
neuroprotective effect of photoreceptors involved a blockade
of L-type voltage-gated calcium channels, theoretically preventing activation of apoptosis by high levels of calcium influx [1,27]. The present study began with the simple goal of
confirming and extending the important initial observation in
rd mice by applying the pharmaceutical treatment to a naturally-occurring canine disease with similar molecular causation. Because there are patients that share this molecular cause
with the rd and rcd1 animal models, proof that a calcium channel blocker rescued photoreceptors in both species could lend
support to consideration of a clinical trial in this form of RP. It
would seem prudent now, considering our negative result in
the rcd1 model, to perform further animal experiments, rather
than accelerate forward to human intervention.
On the other hand, different results in different species
must be viewed for the complexity that they represent. In the
two sets of experiments in the PDE6B mutant animals, there
are not only species differences but also model differences
and variations in the exact conduct of the individual experiments, all of which could complicate comparison of final results. For example, D-cis-diltiazem provided measurable protection in later stages of the murine disease model [1]. It may
45
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